Prof. Christos Zouboulis (Dessau Medical Centre, Germany) presented 2-year data from the ongoing BE HEARD EXT open-label extension study (NCT04901195), which included 556 participants with hidradenitis suppurative (HS) from the phase 3 BE HEARD 1 and 2 trials (NCT04242446 and NCT04242498) [1]. In BE HEARD EXT, participants achieving HiSCR≥90 at 1 year continued bimekizumab 320 mg every 4 weeks; those with a HiSCR<90 continued on a dose of 320 mg every 2 weeks.
The baseline characteristics included a mean age of 36.3 years, 53.8% were women, a mean disease duration of 7.4 years, and all participants had Hurley stage 2 or 3. Prof. Zouboulis highlighted a mean count of 16.9 abscesses and inflammatory nodules and 3.8 draining tunnels.
The results for various HiSCR rates over time showed a sustained treatment effect over 2 years with 85.4% reaching HiSCR50, 77.1% HiSCR75, 57.6% HiSCR90, and 44.2% HiSCR100. In addition, the IHS4 score changes from baseline were maintained: -70.3 at year 1 and -79.8% at year 2, with a baseline mean IHS4 of 35.6 and a 96-week mean of 7.2. Further, the mean number of draining tunnels changed from 3.8 at baseline to 1.1 after 2 years. Prof. Zouboulis indicated that until 1 year ago only surgical treatment had been able to induce a change of disease category.
No new safety signals were observed up to year 2. The most common adverse events were HS (20.5%), COVID-19 (15.3%), and oral candidiasis (10.5%). “We can now have drugs that can change disease category from severe to moderate and from moderate to mild, and this is completely new,” Prof. Zouboulis emphasised in his conclusion.
- Zouboulis C, et al. Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT. D3T01.3A, EADV Congress 2024, 25–28 September, Amsterdam, the Netherlands.
Copyright ©2024 Medicom Medical Publishers
Medical writing support was provided by Karin Drooff MPH
Posted on
Previous Article
« JAK1 inhibitor shows promising long-term efficacy in PN Next Article
Second-generation selective PDE-4 inhibitor shows promise in AD »
« JAK1 inhibitor shows promising long-term efficacy in PN Next Article
Second-generation selective PDE-4 inhibitor shows promise in AD »
Table of Contents: EADV 2024
Featured articles
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Online First
Delgocitinib cream outperforms oral alitretinoin in chronic hand eczema
Second-generation selective PDE-4 inhibitor shows promise in AD
HS: Bimekizumab shows sustained 2-year efficacy
JAK1 inhibitor shows promising long-term efficacy in PN
Deuruxolitinib significantly improves hair satisfaction in alopecia areata
Familial hidradenitis suppurativa associated with higher risk for metabolic disease
Targeting IL-17A offers a promising treatment perspective in hidradenitis suppurativa
Imsidolimab potential future therapeutic avenue for generalised pustular psoriasis
Prurigo nodularis: long-term treatment reduces relapse events
Atopic dermatitis early in life imposes a lifelong psychosocial burden
PsoBest registry: Biologics have become the first choice in moderate-to-severe psoriasis
Topical pan-JAK inhibitor mitigates inflammatory biomarkers in frontal fibrosing alopecia
Atopic hand eczema: similar treatment success for dupilumab and topical delgocitinib
IL-13 inhibitor shows safety and efficacy in AD over 3 years
Semaglutide: also beneficial for patients with HS?
Advanced BCC: histological subtype and time to complete response may predict tumour recurrence
New targets identified for chronic wound healing
Related Articles
December 20, 2018
Psoriasis management online?
August 19, 2020
Baricitinib beneficial in head and neck AD
August 26, 2019
Treating keloids with lasers
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com